Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis
about
Viscosupplementation for the treatment of osteoarthritis of the kneeThe effect of spinal manipulative therapy on experimentally induced pain: a systematic literature review.A randomized controlled trial of acupuncture for osteoarthritis of the knee: effects of patient-provider communication.Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study.How to define responders in osteoarthritis.Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence.Comparing the performance of the EQ-5D and SF-6D when measuring the benefits of alleviating knee pain.Efficacy of single-dose hyaluronic acid products with two different structures in patients with early-stage knee osteoarthritis.A randomized double-blind placebo-controlled trial to investigate the effectiveness and safety of a novel green-lipped mussel extract -BioLex® -for managing pain in moderate to severe osteoarthritis of the hip and kneeTherapeutic efficacy of three hyaluronic acid formulations in young and middle-aged patients with early-stage meniscal injuries.Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis.Improvement in condition-specific and generic quality of life outcomes in patients with knee osteoarthritis following single-injection Synvisc: results from the LOBRAS study.Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.Cost-effectiveness of total knee replacement: a prospective cohort study.
P2860
Q24246179-F1FD747A-EF21-4C43-84A8-42B004A0B28DQ30530333-810F1C2B-4A51-4168-A064-41249B33BDFDQ34117652-44CFF3A9-BBE2-45B7-94D3-8FD12F0B85C3Q35410280-AE2FEA73-F197-400C-A195-8D6D3C2E7041Q36949072-9EC4A8CA-FE39-4707-B10B-4FD37DEE007CQ37216581-4BF8E96A-3648-4AF5-99FA-4B7E0AFB073FQ37289472-3A6FF4A0-2DA0-47A2-A1A8-BE7E474D6097Q37478669-57F49DA1-0D9F-4A32-9F4F-837730D34B7CQ38638647-1AD71BAE-9FA6-46AA-AF90-18D86E7FBB2FQ38661456-5E655BEE-4D9A-4BD8-81C0-3D403CB21B45Q38901250-9EDA58F3-F9FA-45F7-89AC-2D0E57F478B1Q39184657-7D451AD0-BA4E-4A4B-99E7-53D7CDB98F0CQ44256604-DB69C204-14CE-4A96-822D-F53E260244BEQ45833487-E79F9E47-AF23-41DC-96F4-BA7E5905DE5B
P2860
Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Evaluation of WOMAC 20, 50, 70 ...... G-F 20 for knee osteoarthritis
@ast
Evaluation of WOMAC 20, 50, 70 ...... G-F 20 for knee osteoarthritis
@en
type
label
Evaluation of WOMAC 20, 50, 70 ...... G-F 20 for knee osteoarthritis
@ast
Evaluation of WOMAC 20, 50, 70 ...... G-F 20 for knee osteoarthritis
@en
prefLabel
Evaluation of WOMAC 20, 50, 70 ...... G-F 20 for knee osteoarthritis
@ast
Evaluation of WOMAC 20, 50, 70 ...... G-F 20 for knee osteoarthritis
@en
P2093
P2860
P356
P1476
Evaluation of WOMAC 20, 50, 70 ...... G-F 20 for knee osteoarthritis
@en
P2093
Goldsmith CH
Polisson R
Raynauld JP
Torrance GW
P2860
P304
P356
10.1136/ARD.2004.026443
P407
P577
2004-11-25T00:00:00Z